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Abstract
Japanese encephalitis (JE) virus is the most common vaccine-preventable cause of encephalitis in 
Asia. Recent progress in the development and availability of improved JE vaccines has revitalized 
the prospects for JE control. There now are a number of safe and effective vaccines, two WHO 
prequalified vaccines available for pediatric use, at least one vaccine considered affordable for use 
in lower income countries, and a GAVI Alliance commitment to provide financial support to 
eligible countries for campaigns for children aged 9 months through 14 years. While challenges 
remain, this tremendous progress means there is a better opportunity than at any time in the past to 
prevent the substantial morbidity and mortality from this disease.
Japanese encephalitis (JE) virus, a mosquito-borne flavivirus, is the most common vaccine-
preventable cause of encephalitis in Asia. Each year, an estimated 67,900 JE cases occur. 
About 75% of these cases occur in children aged <15 years with an annual incidence of 5.4 
cases per 100,000 children [1]. The case fatality rate is 20–30% and 30–50% of survivors 
have long-term physical or cognitive sequelae. Given its incidence and severity, JE is a 
major public health problem.
There is no antiviral therapy or other medication available to mitigate the effects of JE virus 
infection. The mosquitoes that transmit JE virus breed in rice paddies and other open water 
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sources, so vector control measures are resource intensive and have limited effectiveness. 
Human vaccination is the most effective means of prevention and the WHO recommends 
that JE vaccine be incorporated into immunization programs in all areas where JE is a public 
health problem [2]. An international group of partners has proposed a control target of 0.5 
cases per 100,000 children aged <15 years in each endemic country [3].
In several Asian countries, inactivated mouse brain-derived JE vaccine has been used for 
many years to effectively control disease [2]. However, this formulation is difficult to 
produce, relatively expensive, requires multiple doses, and has been associated with rare 
serious hypersensitivity and neurological adverse events. These factors have resulted in the 
limited use of JE vaccine in many JE-endemic countries. Fortunately, recent progress in the 
development and availability of improved JE vaccines has revitalized the prospects for JE 
control.
Three types of newer JE vaccines are increasingly available for international use. These 
include the live attenuated SA 14-14-2 JE vaccine, inactivated Vero cell culture-derived JE 
vaccines and a live attenuated chimeric virus vaccine. Manufactured by the Chengdu 
Institute of Biological Products, the SA 14-14-2 vaccine has been used in China for over 20 
years and has been shown to be safe and effective in clinical trials and immunization 
programs [4–7]. The vaccine is approved as a single primary dose for children aged ≥8 
months, so it can be easily incorporated into the routine immunization schedule and is often 
coadministered with measles vaccine around 9 months of age. SA 14-14-2 vaccine is 
licensed or available for use in at least nine Asian countries. In a major milestone, SA 
14-14-2 vaccine was prequalified by WHO in October 2013, the first JE vaccine to be 
prequalified for pediatric use [8]. This means the vaccine meets WHO standards for quality, 
safety and efficacy, and enables procurement by UN agencies and inclusion in the GAVI 
portfolio of vaccines.
Inactivated Vero cell culture-derived vaccines are produced in several countries. One Vero 
cell culture-derived vaccine manufactured by Valneva Scotland Limited (formerly Intercell 
Biomedical) is licensed in 38 countries and is primarily used in adult and pediatric travelers 
from nonendemic countries [9,10]. Following technology transfer from Intercell, Biological 
E produced a similar vaccine in India that is now prequalified by WHO for use in adults 
aged 18 through 49 years and children aged 1 and 2 years [11]. Finally, Sanofi Pasteur 
produces a live attenuated JE chimeric virus vaccine that has recently been licensed in four 
countries [12,13].
In addition to vaccine safety, effectiveness and programmatic feasibility, vaccine 
affordability is essential to enable sustainable JE immunization in low- and middle-income 
endemic countries. This is especially important as high coverage will be needed long term 
since JE virus is maintained in an enzootic cycle between mosquitoes and amplifying animal 
hosts and nonimmune people will remain at risk. Chengdu Institute of Biological Products 
has guaranteed a maximum public sector price for SA 14-14-2 vaccine for low-income 
countries; the price is comparable to the international public sector price for measles vaccine 
and is guaranteed through 2033 [14]. This price will allow low-income Asian countries to 
consider implementation of JE immunization programs. Analyses in several countries have 
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shown that JE immunization with SA 14-14-2 vaccine is a cost–effective public health 
measure with substantial impact [15–17]. Taking into consideration nonmedical costs and 
costs due to sequelae, immunization may result in cost savings. Therefore, JE immunization 
has the potential to relieve JE’s economic burden on national health systems.
Another exciting development that greatly improves prospects for JE control came in 
November 2013 with the decision by the GAVI Alliance Board to provide funding support 
for catch-up vaccination campaigns for children aged 9 months through 14 years in eligible 
countries interested in introducing JE vaccine for children [18]. Unlike some other vaccine-
preventable childhood diseases, JE burden is not concentrated in infancy or early childhood. 
Further, since JE is not transmitted from person to person, JE immunization only provides 
benefit to the vaccine recipient and does not result in herd immunity. The control strategy 
with the greatest impact is a one-time campaign in the highest risk age groups (e.g., children 
aged 9 months through 14 years) followed by the incorporation of JE vaccine into the 
routine childhood immunization program [2]. The availability of funding for initial 
immunization campaigns in resource-limited countries is a critical element of JE control, 
and GAVI financing will help overcome this barrier in eligible countries.
Current prospects for JE control are promising. There are a number of safe and effective 
vaccines. Two of these vaccines are WHO prequalified and at least one is considered 
affordable for use in low-income countries. Finally, GAVI has committed to providing 
financial support to eligible countries for initial vaccination campaigns. However, several 
issues still need to be addressed [19–22].
Understanding and awareness of disease burden in all JE-endemic countries need to be 
increased to provide evidence and guide countries and National Immunization Technical 
Advisory Groups in decisions about vaccine introduction, immunization policy, and 
program delivery. JE surveillance has markedly improved during the last decade. However, 
substantial gaps remain in many countries with regards to collection of information or 
quality of the data. A recent assessment suggested that JE cases reported to WHO 
underestimate by 10-times the true number of cases occurring annually [1]. Primary 
obstacles in defining disease burden include limited financial resources for surveillance 
programs and challenges with incorporating these programs into existing infrastructure or 
networks. A further concern is limited access to diagnostic and confirmatory testing. To 
address this issue, a WHO JE laboratory network, modeled after the polio and measles 
laboratory networks, has been developed [22,23]. This network aims to build laboratory 
capacity to support public health surveillance through training workshops, technical support, 
and proficiency and confirmatory testing. This network needs to be strengthened in some 
areas to ensure equitable access to good quality diagnostic testing.
For maximum impact, the introduction of JE vaccination will require both the incorporation 
of JE vaccine into a country’s routine childhood immunization schedule and catchup 
campaigns in children as old as 14 years. Older children are difficult to reach, particularly if 
they no longer attend school. Countries will need to develop strategies to implement JE 
vaccination in these older age groups, as has been done with measles and rubella vaccines. 
They must also have the capacity to monitor and evaluate the introduction [24].
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To date, local transmission of JE virus has only been documented in Asia and the western 
Pacific. As a result, there is limited global awareness of this devastating disease. Large 
outbreaks sometimes generate temporary interest, but the disease and major achievements in 
its control have received little attention [25]. Several organizations, including the Bill & 
Melinda Gates Foundation, have committed resources to JE surveillance and control. 
However, dedicated and consistent advocacy will be needed to ensure that JE control 
remains on national, regional and international agendas. This is consistent with the WHO 
Global Vaccine Action Plan 2011–2020 goal to introduce and ensure equitable access to 
new and improved vaccines [26].
JE control is feasible and within reach. Japan, South Korea, Taiwan and Thailand have 
successful JE immunization programs that dramatically reduced disease incidence [1,21]. 
Other countries, such as China, India and Nepal have made substantial progress in the last 
few years [17,21,22]. Recent developments that include improved international availability 
of vaccines, prequalification of vaccines for pediatric use, and GAVI funding for JE vaccine 
introduction have transformed the landscape of JE control. Better information on the 
distribution and burden of JE disease, and the value and impact of vaccination is 
increasingly available. While challenges remain, this tremendous progress means there is a 
better opportunity than at any time in the past to prevent the substantial morbidity and 
mortality from this disease. We are now at the point when achieving the JE control target is 
realistic. Progress towards the goal will require ongoing efforts to define and improve 
awareness of the burden of JE illness and the benefits of JE vaccination, adequate financial 
resources, support to National Immunization Technical Advisory Groups in their decision-
making process, and the continued engagement of donor and international organizations. As 
with all public health efforts, meaningful progress will require sustained commitment. With 
such commitment, we have the opportunity to save and improve the lives of millions of 
children.
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